NCT04318080View on ClinicalTrials.gov

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 20, 2020

Primary Completion Date

December 12, 2022

Study Completion Date

August 29, 2024

Conditions
Classical Hodgkin Lymphoma
Interventions
DRUG

Tislelizumab

200 milligrams (mg) intravenously every 3 weeks (Q3W)

Trial Locations (4)

48201-2013

Barbara Ann Karmanos Cancer Institute, Detroit

37920-1511

University of Tennessee Medical Center, Knoxville

84112-5550

Huntsman Cancer Institute, Salt Lake City

VIC 3168

Monash Health, Clayton

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
collaborator

Lymphoma Study Association

OTHER

lead

BeiGene

INDUSTRY